Learn More
OBJECTIVE To study the effects of selective serotonin reuptake inhibitors (SSRIs) on pregnancy outcome. METHODS We performed a population-based study of women exposed to SSRIs during pregnancy (n = 1782). Data were derived from a national project in Finland, established by 3 governmental organizations. In that project, the Drug Reimbursement Register, the(More)
BACKGROUND Prenatal exposure to selective serotonin reuptake inhibitors (SSRIs) may increase risk for congenital malformations and adverse perinatal outcome. OBJECTIVE This article reviews the published literature on exposure to SSRIs in utero and during lactation. METHODS Literature search in PubMed. RESULTS There is no conclusive evidence for(More)
OBJECTIVE To assess whether use of specific selective serotonin reuptake inhibitors (SSRIs) or venlafaxine in early pregnancy is associated with an increased risk of birth defects, with emphasis on cardiovascular birth defects even when accounting for lifestyle or other familial confounding. DESIGN Multicountry population based cohort study, including(More)
BACKGROUND Prescribing drugs to pregnant women requires the balancing of benefits and risks. Only a small proportion of drugs are known to be harmful to the fetus, but for the vast majority of drugs little evidence of fetal safety exists. AIM To determine the prescription pattern of potentially and clearly harmful prescription drugs during pregnancy with(More)
INTRODUCTION Perinatal health outcomes other than major congenital anomalies in offspring of women with epilepsy (WWE) have not been widely studied, and results of previous studies are conflicting and are mostly based on small numbers. Antiepileptic drugs (AEDs) pass through the placenta and may affect neonatal outcome. METHODS This register-based study(More)
Cerebral venous thrombosis (CVT) is an uncommon cause of stroke, accounting to less than 1% of all strokes. We describe a pregnant woman with a massive CVT in early pregnancy, complicated by status epilepticus. The mother was treated with levetiracetam, lacosamide, and enoxaparin throughout pregnancy. A male infant was born on pregnancy week 36, weighing(More)
BACKGROUND Antidepressants have been commonly used by women of childbearing age. Recent studies suggest that paroxetine, a selective serotonin reuptake inhibitor (SSRI), might specifically increase teratogenic risk. OBJECTIVES The purpose of this study was to quantify first-trimester exposure to paroxetine and birth defects and examine potential sources(More)
OBJECTIVE In 2005-2006, several studies noted an increased risk of cardiovascular birth defects associated with maternal use of paroxetine compared with other antidepressants in the same class. In this study, the authors sought to determine whether paroxetine was associated with an increased risk of cardiovascular defects in infants of women exposed to the(More)
OBJECTIVE Using national register data, the authors examined the relationship between prenatal selective serotonin reuptake inhibitor (SSRI) treatment and pregnancy complications, accounting for psychiatric diagnoses related to SSRI use. METHOD This was a population-based prospective birth cohort study using national register data. The sampling frame(More)
Objective. To examine the use of prescription drugs in Finnish women before and during pregnancy and lactation. Methods. A register-based study linking four nation-wide registers in Finland: the Maternal Grants Register, the Drug Prescription Register, and the Special Refund Register (all maintained by the Social Insurance Institution in Finland; KELA),(More)